AIM ImmunoTech (AIM) investor relations material

Executive summary

• Special Meeting scheduled for July 15, 2026, to address critical capital structure and compliance matters.

• Board unanimously recommends voting in favor of all seven proposals to support ongoing operations and financial flexibility.

• Proposals focus on authorizing significant issuances of common stock and a potential reverse stock split to maintain exchange compliance and liquidity.

• Failure to approve proposals may jeopardize the company's ability to raise capital and continue operations.

Voting matters and shareholder proposals

• Proposal 1: Approve issuance of >19.99% of shares upon exercise of Class H warrants, tied to a May 2026 inducement offer.

• Proposal 2: Approve issuance of >19.99% of shares upon exercise of Class I warrants from a May 2026 securities purchase agreement.

• Proposal 3: Approve issuance of >19.99% of shares upon exercise of Class J warrants from a June 2026 agreement.

• Proposal 4: Approve issuance of >19.99% of shares upon conversion of a February 2024 promissory note.

• Proposal 5: Approve issuance of >19.99% of shares upon conversion of a November 2025 promissory note.

• Proposal 6: Approve amendments for a reverse stock split at a ratio up to 1-for-25, at Board discretion.

• Proposal 7: Approve adjournment of the meeting if more time is needed to solicit votes.

Board of directors and corporate governance

• Board strongly recommends voting “FOR” all proposals to ensure compliance and operational continuity.

• Board retains discretion on timing and ratio of reverse stock split, if approved.

• Principal stockholders and directors collectively own a small percentage of outstanding shares.